| Identification | More | [Name]
Levofloxacin hydrochloride | [CAS]
100986-85-4 | [Synonyms]
(3s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7h-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid monohydrochloride
LEVOFLOXACIN HCL
LEVOFLOXACIN HEMIHYDRATE
(s)-ofloxacin
7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylicacid,2,3-dihydro-9-fluoro-3-m
dr3355
hemihydrate,(s)-ethyl-10-(4-methyl-1-piperazinyl)-7-oxo
Levofloxacin base
LEVOFLOXACIN 99%
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic Acid Hemihydrate
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)-(9CI)
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)-
Cravit
HR 355
Levaquin
RWJ 25213-097
Tavanic
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazin-yl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
Levofloxacin
L-Ofloxacin | [EINECS(EC#)]
600-146-0 | [Molecular Formula]
C18H20FN3O4 | [MDL Number]
MFCD03265511 | [Molecular Weight]
361.37 | [MOL File]
100986-85-4.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R22:Harmful if swallowed.
R42/43:May cause sensitization by inhalation and skin contact .
R68:Possible risk of irreversible effects.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S36:Wear suitable protective clothing . | [RIDADR ]
UN 1648 3 / PGII | [WGK Germany ]
3
| [RTECS ]
UU8815550
| [HS Code ]
29349990 | [Hazardous Substances Data]
100986-85-4(Hazardous Substances Data) | [Toxicity]
LD50 oral in rat: 1478mg/kg |
| Hazard Information | Back Directory | [Description]
Levofloxacin, the optically active S-isomer of the fluoroquinolone antibiotic ofloxacin,
is two to four times more potent than ofloxacin with reportedly less side effects in treating
infections of the lower respiratory and urinary tract, prostate infections and sexually
transmitted diseases. It has broad and potent antibacterial activity over common Grampositive
and -negative aerobic pathogens and obligate anaerobes. Different from the cephem
antibiotics, levofloxacin is unique in its marked selectivity against members of the family
Enterobacteriaceae and its negligible effect on predominant anaerobes. Levofloxacin also
exhibits satisfactory antimicrobial effects in surgical infections and it may be used for
treatment of gastrointestinal infections such as traveler’s diarrhea associated with the
pathogenic Enterobacteriaceae. | [Chemical Properties]
Slight yellow powder | [Originator]
Daiichi (Japan) | [Uses]
Antibacterial. | [Definition]
ChEBI: Levofloxacin is an optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase. It has a role as a DNA synthesis inhibitor, an antibacterial drug, a topoisomerase IV inhibitor and an EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor. It is a quinolone antibiotic, a fluoroquinolone antibiotic and a 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid. It is an enantiomer of a dextrofloxacin. | [Manufacturing Process]
()-3-Acetoxymethyl-7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine (m.p. 73-
74°C) was synthesized by hydrogenation of a compound prepared from 2,3-
difluoro-6-nitrophenol, 1-acetoxy-3-chloro-2-propane and potassium iodide.
The hydrogenation was carried out on Raney nickel. The resulting compound
was dissolved in THF, and 3,5-dinitrobenzoyl chloride and pyridine were added
thereto, followed by heating at 60°C for 3 hours. The mixture was
concentrated, and the concentrate was dissolved in ethyl acetate, washed
successively with diluted hydrochloric acid, an aqueous solution of sodium
bicarbonate and water, dried over anhydrous sodium sulfate and concentrated.
Addition of n-hexane to the concentrate caused precipitation of yellow crystals
of a racemate. The yield of 3,5-dinitrobenzoyl derivative of the ()-3-
acetoxymethyl-7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine 3.93 g.
To 2.0 ml of Amberlite XAD 7 was added 2.0 ml of a 0.05 M phosphoric acid
buffer (pH 7.0) having dissolved therein 20 mg of lipoprotein lipase, and the
system was allowed to stand at room temperature for 18 hours to thereby
adsorb the enzyme onto the resin. The resin was filtered. A solution of 250
mg of 3,5-dinitrobenzoyl derivative of ()-3-acetoxymethyl-7,8-difluoro-2,3-
dihydro-4H-[1,4]benzoxazine as a substrate in 25 ml of a mixed solvent of
benzene and n-hexane (4:1 by volume) was added to the resin, followed byallowing to react at 37°C for 4 hours. It was obtained 117 mg of a 3,5-
dinitrobenzoyl derivative of the (-)-3-acetoxymethyl-7,8-difluoro-2,3-dihydro-
4H-[1,4]benzoxazine and 65 mg of a derivative of the (-)-3-acetoxymethyl-
7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine.
In 135 ml THF was dissolved 3.03 g of a 3,5-dinitrobenzoyl derivative of (-)-
3-acetoxymethyl-7,8-difluoro-2,3-dihydro-4H-[1,4]benzoxazine, and 135 ml of
ethanol and 30 ml of 1.0 N potassium hydroxide were added to the solution.
After 30 min 3 ml of acetic acid was added thereto for neutralization. The
mixture was concentrated. The solid was subjected to column chromatography
using 40 g of silica gel and eluted with chloroform/methanol to obtain 1.17 g
of (-)-7,8-difluoro-2,3-dihydro-3-hydroxymethyl-4H-[1,4]benzoxazine; [α]D22
= -14.1° (c = 1.80, CHCl3).
To 1.17 g of (-)-7,8-difluoro-2,3-dihydro-3-hydroxymethyl-4H-[1,4]
benzoxazine was added 2.77 g of thionyl chloride in pyridine. The reaction
mixture was concentrated and the concentrate was subjected to column
chromatography using 40 g of silica gel and eluted with chloroform to obtain
1.18 g of the reaction product as a colorless oily product. This product was
dissolved in 30 ml of dimethyl sulfoxide, and 0.41 g of sodium borohydride
was added thereto, followed by heating at 80-90°C for 1 hour. The reaction
mixture was dissolved in 500 ml of benzene, washed with water to remove
the dimethyl sulfoxide, dried over anhydrous sodium sulfate and concentrated
under reduced pressure. The concentrate was subjected to column
chromatography using 40 g of silica gel and eluted with benzene to obtain
0.80 g of (-)-7,8-difluoro-2,3-dihydro-3-methyl-4H-[1,4]benzoxazine as a
colorless oily product; [α]D25 = -9.6° (c = 2.17, CHCl3). Optical Purity: >99%
e.e.
To 1.13 g of (-)-7,8-difluoro-2,3-dihydro-3-methyl-4H-[1,4]benzoxazine was
added 1.58 g of diethyl ethoxymethylenemalonate, and the mixture was
stirred at 130-140°C for 70 min. The reaction mixture was subjected to
column chromatography using 50 g of silica gel and eluted with chloroform to
obtain 2.47 g of diethyl [(-)-7,8-difluoro-3-methyl-2,3-dihydro-4H-[1,4]
benzoxazin-4-yl]methylenemalonate. This product was dissolved in 5 ml of
acetic anhydride, and 10 ml of a mixture of acetic anhydride and concentrated
sulfuric acid (2/1 by volume) with stirring under ice-cooling, followed by
stirring at 50-60°C for 40 min. To the reaction mixture were added ice and an
aqueous solution of sodium bicarbonate, and the product was extracted three
times with 150 ml portions of chloroform. The combined extract was washed
with water, dried over anhydrous sodium sulfate and concentrated. The
precipitate was washed with a small amount of diethyl ether to yield 1.32 g of
(-)-ethyl 9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]
benzoxazine-6-carboxylate.
In 12 ml of acetic acid was dissolved 1.20 g of the resulting compound, and
25 ml of concentrated hydrochloric acid was added, followed by refluxing at
120-130°C for 90 min. Upon allowing the reaction mixture to stand at room
temperature, colorless crystals were precipitated, which were collected by
filtration and washed successively with a small amount of water, ethanol and
diethyl ether to obtain 0.96 g of (-)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-
7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid.
In 30 ml of diethyl ether was suspended 324 mg of the resulting compound,and a large excess of boron trifluoride ethyl etherate was added thereto,
followed by stirring at room temperature for 30 min to form a chelate
compound. The product was collected by filtration and washed with a small
amount of diethyl ether to obtain 373 mg of a powder. The powder was
dissolved in 7 ml of dimethyl sulfoxide, and 136 mg of N-methylpiperazine
and 228 mg of triethylamine were added thereto, followed by stirring at room
temperature for 17 hours. The reaction mixture was concentrated to dryness
under reduced pressure, and to the solid were added 15 ml of 95% methanol
and 0.31 ml of triethylamine. The resulting mixture was refluxed for 3 hours.
The reaction mixture was concentrated under reduced pressure, and the
residue was filtered and washed successively with a small amount of ethanol
and diethyl ether to obtain 350 mg of a white powder. Recrystallization from a
mixed solvent of ethanol and thick aqueous ammonia gave 230 mg of S-(-)-
ofloxacin (Levofloxacin).
Melting Point: 225-227°C (with decomposition); [α]D23 = -76.9° (c = 0.39,
0.05 N NaOH). | [Brand name]
Iquix (Sanofi Winthrop); Levaquin
(Ortho-McNeil); Quixin (Sanofi Winthrop);Cravit. | [Therapeutic Function]
Antibacterial | [Antimicrobial activity]
Levofloxacin is the active component of ofloxacin; d-ofloxacin is without significant antibacterial activity. It exhibits good activity in vitro against Gram-positive cocci (including Str. pneumoniae), Enterobacteriaceae, some fastidious Gram-negative bacilli and Ps. aeruginosa as well as chlamydiae, Mycoplasma pneumoniae, L. pneumophila and M. tuberculosis. MICs for Acinetobacter spp. and Sten. maltophilia are 0.06–0.25 and 0.5–2.0 mg/L, respectively. Activity against anaerobes is moderate to low.
| [General Description]
Chemical structure: quinolone | [Pharmaceutical Applications]
For molecular weight and structure, see ofloxacin . Levofloxacin is the l-isomer of ofloxacin. | [Pharmacokinetics]
Oral absorption: >95%
Cmax 500 mg oral: c. 5 mg/L after 1.5–2 h
750 mg oral: c. 8 mg/L after 1.5–2 h
500 mg intravenous (90-min infusion): c. 6 mg/L end infusion
750 mg intravenous (90-min infusion) ：c. 12 mg/L end infusion
Plasma half-life ：6–8 h
Volume of distribution：0.6–0.8 L/kg
Plasma protein binding： <25%
Co-administration with antacids, calcium, sucralfate and heavy metals decreases bioavailability and AUC. No interactions with warfarin or theophylline have been observed. Co-administration of a non-steroidal anti-inflammatory drug may increase the risk of convulsions. It undergoes limited metabolism and is primarily eliminated unchanged in urine by both glomerular filtration and tubular secretion. The free AUC:MIC ratio for Str. pneumoniae increases from about 55 to 70 when the daily dosage is raised from 500 mg to 750 mg.
It is stable in plasma and does not revert to d-ofloxacin. It undergoes limited metabolism and is primarily eliminated unchanged in the urine. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion also occurs. Concomitant administration of either cimetidine or probenecid reduces renal clearance by approximately onethird. Clearance is reduced and half-life is prolonged in patients with impaired renal function (creatinine clearance <50 mL/min) requiring dosage adjustment in such patients. | [Clinical Use]
Acute bacterial sinusitis
Acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia
Uncomplicated and complicated skin and skin structure infections
Uncomplicated and complicated urinary infections including acute pyelonephritis
Chronic bacterial prostatitis | [Side effects]
Side effects have been reported in 6–7% of patients and include fever, rash and other events common to the group. Elderly patients are at increased risk of developing severe tendon disorders including rupture, a risk increased by concomitant corticosteroid therapy. | [Drug interactions]
Potentially hazardous interactions with other drugs
Aminophylline and theophylline: possibly increased
risk of convulsions.
Analgesics: possibly increased risk of convulsions
with NSAIDs.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with amiodarone - avoid.
Anticoagulants: anticoagulant effect of coumarins
and phenindione enhanced.
Antimalarials: manufacturer advises avoid
concomitant use with artemether and lumefantrine.
Ciclosporin: half-life of ciclosporin increased by 33%;
increased risk of nephrotoxicity.
Cytotoxics: increased risk of ventricular arrhythmias
with arsenic trioxide.
Tacrolimus: may increase tacrolimus concentration. | [Metabolism]
Levofloxacin is metabolised to a very small extent, the
metabolites being desmethyl-levofloxacin and levofloxacin
N-oxide.
These metabolites account for <5% of the dose and are
excreted in urine. Excretion is primarily by the renal route |
|
|